Abstract

PURPOSE:The benefit of Carvedilol (Carv) compared to Metoprolol (Meto) in patients with left ventricular mechanical dyssynchrony (LVMD) receiving cardiac resynchronization therapy (CRT) has not been well delineated. The effect of maximum tolerated dose of these drugs on cardiac function, LVMD and response to CRT was studied.

METHODS:We studied 97 consecutive patients with CRT (male 70, age 69.7± 9.5 years). Patients with atrial fibrillation were excluded. Patients were divided into Group I, 31 patients on Carv (dose 22.3± 17.1mg/d, 27 patients started 23.3± 29.6 months before CRT and all continued for 20.0± 11.0 months after CRT) and Group II, 66 patients on Meto (dose 60.4± 43.3mg/day, 56 patients on Succinate, 10 patients on Tartrate, 52 patients started 21.5± 25.0 months before CRT and all continued for 21.6± 12 months after CRT). The time difference (TPW-TDI) between QRS onset to the end of LV ejection by pulsed wave Doppler (PW) and QRS onset to the end of the systolic wave in basal lateral and septal segments with greatest delay by tissue Doppler imaging (TDI) was measured before CRT and 15.1 ± 10.6 months after CRT. TPW-TDI > 50ms was defined as LVMD. A decrease of left ventricular end systolic volume ≥15% after CRT was defined as a positive response to CRT.

RESULTS:During follow-up by echo/Doppler studies, patients on Meto had greater improvement in LVEF (19.7± 6.6% to 27.9± 13.6%, p< 0.0001) than in patients on Carv (22.3± 6.8% to 25.7± 12.0%, p=0.17). More patients on Meto (35/66, 53%) responded to CRT compared to patients on Carv (9/31, 29%, p< 0.05). TPW-TDI significantly decreased in both groups (p< 0.0001 and p= 0.01). There were no significant differences in mortality and hospitalization between these two groups (p= NS).

CONCLUSION:Positive response to CRT and improvement of cardiac function is significantly greater in Meto compared to Carv.

CLINICAL IMPLICATIONS:The study demonstrated the impact of Metoprolol in patients with CRT.

Return to: COMPARISON BETWEEN CARVEDILOL AND METOPROLOL IN PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY

Copyright in the material you requested is held by the American College of Chest Physicians (unless otherwise noted).
This email ability is provided as a courtesy, and by using it you agree that that you are requesting the material
solely for personal, non-commercial use, and that it is subject to the American College of Chest Physicians’ Terms of Use.
The information provided in order to email this topic will not be used to send unsolicited email, nor will it be
furnished to third parties. Please refer to the American College of Chest Physicians’ Privacy Policy for further information.

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username
(required)

Email Address
(required)

Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.